Contact us
Menu
Contact us
Feldan Australia

Feldan Australia Pty Ltd (Feldan Australia) strengthens Feldan Therapeutics' global clinical development capabilities by engaging with the local clinical research ecosystem and ensuring compliance with applicable governance and legal requirements.

Feldan Australia is a wholly owned subsidiary of Feldan Therapeutics. It provides local operational oversight in Australia and facilitates collaboration with clinical research organizations (CROs), investigational sites, healthcare professionals and other stakeholders to support the execution of Feldan’s clinical research activities in accordance with Good Clinical Practice (GCP).

 Governance 
Feldan Australia conducts its activities within Feldan's global governance framework while complying with all applicable Australian legal , regulatory and corporate requirements. 

Board of Directors

The Board of Directors of Feldan Australia brings together expertise in biotechnology, corporate governance, clinical development, commercialization and international business to support the Company's strategic objectives. It is composed of:

 

Mario Pennisi

Mario Pennisi

Board Member

Elisabeth Sandoval Little

Elisabeth Sandoval Little

Board Member

François-Thomas Michaud

François-Thomas Michaud

Board Member

Vincent Ménard

Vincent Ménard

Board Member

Clinical Research Activities & Research Environment

Feldan Australia oversees the Australian component of Feldan-sponsored clinical studies, including the Phase 1 First-in-Human single and multiple ascending dose escalation study evaluating intralesional FLD-103 in basal cell carcinoma (BCC), conducted across Australia and the United States. 

Australia provides a well-established environment for clinical research, supported by experienced investigators, internationally recognized research institutions and a robust regulatory framework. The country’s strong clinical infrastructure and high-quality research standards make it an attractive location for early-phase clinical development.

Epidemiology

Basal cell carcinoma (BCC), the indication investigated in the FLD-103 Phase 1 study, has a high incidence in Australia, reflecting high cumulative ultraviolet (UV) exposure and a population with increased susceptibility to skin cancers. This epidemiological context supports access to an eligible patient population within an established clinical research environment.

*FLD-103 is an investigational therapeutic candidate and has not been approved for commercial use by any regulatory authority.
*This page is intended for general informational purposes only and does not constitute an offer, solicitation, or invitation to participate in a clinical study.